Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis. - Wikidata - wikimedia - TriplyDB

Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.

Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.

http://www.wikidata.org/entity/Q37122878

about

Targeting MT1-MMP as an ImmunoPET-Based Strategy for Imaging Gliomas Molecular Imaging of Ovarian Cancer Advancing Immune and Cell-Based Therapies Through Imaging.

P2860

Q27335251-06DAB29F-CB1A-46A1-952F-173EDA55F77A Q37305724-DB301A82-C354-46A6-B848-E1A56C4E79B7 Q39167485-1C6821E6-4B78-458F-AD7E-48A206234B97

P2860

Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis.

http://www.wikidata.org/entity/Q37122878

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 02 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Preclinical 89Zr Immuno-PET of ...... cer and Lymph Node Metastasis.

@en

Preclinical 89Zr Immuno-PET of ...... cer and Lymph Node Metastasis.

@nl

type

label

Preclinical 89Zr Immuno-PET of ...... cer and Lymph Node Metastasis.

@en

Preclinical 89Zr Immuno-PET of ...... cer and Lymph Node Metastasis.

@nl

prefLabel

Preclinical 89Zr Immuno-PET of ...... cer and Lymph Node Metastasis.

@en

Preclinical 89Zr Immuno-PET of ...... cer and Lymph Node Metastasis.

@nl

P1433

Q37122878-1A00C120-F301-477D-A774-9E5FB3B58496

P1476

Q37122878-310B681C-4204-498A-9AFC-207D52B00EB1

P2093

Q37122878-2DBF0260-CC19-415D-9CCA-E76EECBCA47C

Q37122878-33886E39-E6B0-4680-9B3D-127996BB707E

Q37122878-5CCF968E-4589-4AA5-A8D5-8CDE999FAE75

Q37122878-6021D6CC-E204-4822-B9BF-26C4D27B8A9D

Q37122878-A110F13E-36D5-404F-AB0B-1D326BBE461D

Q37122878-FA857B22-B875-48C8-B0B0-0FBE211E079D

Q37122878-FB9343DF-73AD-44A1-9355-77317BBD3E03

P2860

Q37122878-0232B4B1-F121-4348-B7D3-93768759E873

Q37122878-1C3F0F9E-CA72-4B78-96E4-5FBE101601BB

Q37122878-1DD51A21-D4A2-456D-94AB-AD27F6ED089D

Q37122878-3FA13485-3FFC-42B4-8C36-67DE2BDD29DF

Q37122878-81235030-F024-4A48-942C-AD67192CC5FB

Q37122878-82FB0F3E-B0FE-4092-B22A-F714BCBD20FB

Q37122878-952C33D4-8EE0-4C4A-A87F-CBE575820F19

Q37122878-96CE831E-4EE6-49E8-AD91-6906D0EB55A1

Q37122878-9776EC88-61F8-4845-9408-F1123FB5FF11

Q37122878-9BB1CB6D-3966-496B-BE3D-25FE84CD222A

P304

Q37122878-213B6F50-00C4-4FB2-8448-4E68592B15B2

P31

Q37122878-98B8A3C4-248C-4C3A-A2D9-6D14EAD2A4FB

P356

Q37122878-C4176FA2-7A7F-4AE1-9679-E5CC5B63186D

P407

Q37122878-A137F098-A1BD-40D9-A285-045134338E87

P433

Q37122878-5D235E54-EB21-4FDC-9B8C-27DADB542DF0

P478

Q37122878-8F7B190F-0B26-444C-9E75-2C4095C362A4

P50

Q37122878-25724628-2D51-4DCF-8C5B-0C2FCE2C3E21

Q37122878-E9E74B3B-73EE-41A9-AC2A-A0774C5F22DC

P577

Q37122878-7C67856F-D122-4D99-BBCC-9CEFCA4FF9FA

P5875

Q37122878-BAB5DFAD-4C73-4367-8268-53F3B2C9A641

P698

Q37122878-8F0DD797-B52B-4847-8E4A-7E7956A5BC56

P921

Q37122878-947BFB38-B823-41A2-8D81-D0E283C61CEC

Q37122878-D52A5386-06B9-4E03-867B-F9C6AA20642D

P932

Q37122878-4224C646-A86C-47E1-ACE6-12D95DEA377B

P356

JNUMED.115.167072

P1433

The Journal of Nuclear Medicine

P1476

Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis

@en

P2093

Brian M Zeglis

http://www.w3.org/2001/XMLSchema#string

Evis Sala

http://www.w3.org/2001/XMLSchema#string

Frank R Wuest

http://www.w3.org/2001/XMLSchema#string

James C Knight

http://www.w3.org/2001/XMLSchema#string

Kuntal K Sevak

http://www.w3.org/2001/XMLSchema#string

Sean D Carlin

http://www.w3.org/2001/XMLSchema#string

Sebastien Monette

http://www.w3.org/2001/XMLSchema#string

P2860

Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations

Cancer statistics, 2015

A three-step strategy for targeting drug carriers to human ovarian carcinoma cells in vitro.

The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?

Recurrent ovarian cancer with multiple lymph nodes metastases successfully treated with lymphadenectomy as secondary cytoreductive surgery: A case report.

CA125 in ovarian cancer

Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab.

PET imaging with ⁸⁹Zr: from radiochemistry to the clinic

Significance of lymphovascular space invasion in epithelial ovarian cancer.

Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature.

P304

771-776

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.115.167072

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

57

http://www.w3.org/2001/XMLSchema#string

P50

Sai Kiran Sharma

P577

2016-02-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292943611

http://www.w3.org/2001/XMLSchema#string

P698

26837339

http://www.w3.org/2001/XMLSchema#string

P921

P932

4959443

http://www.w3.org/2001/XMLSchema#string